Quick Recall

The efficacy of Novavax's COVID-19 vaccine candidate NVX-CoV2373 in the phase 3 trial is _________

198 Votes

7 Likes

LikeAnswersShare

C. 94.4 % Trial phase 3 is efficacy in novavax covid 19 vaccine.

Thanks Dear Hussain
1

View 5 other replies

-C-90.4%- U.S. vaccine manufacturer Novavax, said its COVID-19 vaccine had shown an overall efficacy of 90.4% in trials in the U.S. The Maryland-based company, which tested its two dose ‘NVX-CoV2373’ vaccine on 30,000 in the U.S. and Mexico.

Its 90.4% efficacy that novavax's covid vaccine Candidate has shown

90.4%

Thanks doctor Narendra Kumar
2

View 1 other reply

Novavax vaccine NVX-co 2373 in phase 3 trials ihas 90% efficacy

SUGGESTIVE. OF ...*C* 90 . 4 %

90 percent

90 point 4 c

72.2%

B

Thanks Dr Md Altaf Husain
1

View 2 other replies

Load more answers